Arcellx, Inc. (ACLX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Redwood City, MD, アメリカ. 現CEOは Rami Elghandour.
ACLX を有する IPO日 2022-02-04, 163 名の正社員, に上場 NASDAQ Global Select, 時価総額 $6.72B.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for patients with cancer and other serious diseases. The company's lead candidate, CART-ddBCMA, is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, while its pipeline includes ACLX-001, a dual-targeting immunotherapy combining ARC-T cells and SparX proteins, as well as additional programs targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Founded in 2014 and headquartered in Gaithersburg, Maryland, Arcellx focuses on advancing next-generation cell and protein-based therapies to address unmet medical needs in oncology.
